EyeGate Pharmaceuticals Priced, Nasdaq: EYEG

Late-stage biotech developing a treatment for eye inflammation.

Industry: Health Care

Latest Trade: $2.27 0.00 (0.0%)

First Day Return: -15.9%

Return from IPO: -73.3%

Industry: Health Care

We are a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EGP-437, our first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues through our proprietary innovative drug delivery system, the EyeGate® II Delivery System. EGP-437 is being developed under an NDA. The EyeGate® II Delivery System and EGP-437 are designed to address two major issues in ophthalmic medicine: lack of patient compliance and safety. The EyeGate® II Delivery System features a compact, elegant, and easy-to-use device that we believe has the potential to deliver drugs non-invasively and quickly into the ocular tissues through the use of iontophoresis, which can accelerate the onset of action, dramatically reduce treatment frequency versus eye drops and sustain therapeutic effect. The EyeGate® II Delivery System is easy-to-use, only takes a few minutes to employ and has been utilized to administer more than 1,700 experimental treatments. We hold worldwide commercialization rights to the EyeGate® II Delivery System.
more less
IPO News for EyeGate Pharmaceuticals
more
IPO Data
IPO File Date 06/05/2015
Offer Price $8.50
Price Range $12.00 - $12.00
Offer Shares (mm) 1.2
Deal Size ($mm) $10
IPO Data
IPO Date 07/30/2015
Offer Price $8.50
Price Range $12.00 - $12.00
Offer Shares (mm) 1.2
Deal Size ($mm) $10
Underwriters
more
Company Data
Headquarters Waltham, MA
Founded 2004
Employees 4
Website www.eyegatepharma.com